Navigation Links
AtriCure to Participate at the Thomas Weisel Partners Healthcare Conference and the UBS Global Life Sciences Conference in September
Date:8/25/2008

WEST CHESTER, Ohio, Aug. 25 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during September:

-- The Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 3, 2008. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 10:55 a.m. Eastern time.

-- The UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City on Thursday, September 25, 2008. Mr. Drachman is scheduled to present at 8:30 a.m. Eastern time.

Both presentations will be available live and by replay for 30 days following the presentations at http://www.atricure.com/Investor_Relations .

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
4. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
7. AtriCure Ranked 80th in Deloittes Technology Fast 500
8. AtriCure Reports Third Quarter 2007 Financial Results
9. AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
10. AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
11. AtriCure Appoints Mark A. Collar to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... ... and numeral energies can describe personality traits in humans. Using presidential candidate Donald ... their name and vitality. , “AstroNumerology is not about adding numbers up,” ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Interest is on ... screening tool and as an orthogonal tool for RNAi hit validation. A key reason ... specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The ... on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria ... the country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising Age has ... statement solutions provider, for the tenth consecutive year as a Top 20 Marketing ... Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” category. ...
(Date:5/31/2016)... ... 2016 , ... Super Powder, a supplement produced by Prox Formulas for providing ... athletes, continues to transform the nutritional supplement industry by providing a safe, natural approach ... amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... India , May 27, 2016 ... the instances of hypertension is driving ambulatory blood pressure ... lose their elasticity and their ability to respond to ... pressure. This condition can lead to various cardiovascular disorders ... peripheral vascular disease. These diseases are growing in prevalence ...
(Date:5/27/2016)... 27, 2016 The healthcare sector ... insurance companies all falling under its umbrella.  A rather ... not often talked about, these healthcare companies are still ... is by far the largest consumer of ... Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. ...
Breaking Medicine Technology: